Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay

Leukemia

Volumn 16, Issue 6, 2002, Pages 1167-1175

  Yokota, H ^a   Tsuno, N H ^a   Tanaka, Y ^a   Fukui, T ^b   Kitamura, K ^a   Hirai, H ^a   Osumi, K ^b   Itou, N ^c   Satoh, H ^c   Okabe, M ^d   Nakahara, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Pharmaceutical Company   (Japan)

^c TOHO UNIVERSITY   (Japan)

^d SAPPORO HOKUYU HOSPITAL   (Japan)

Author keywords

Acute lymphoblastic leukemia; e1a2 BCR ABL; Minimal residual disease; Monitoring; Real time RT PCR assay

Indexed keywords

ADULT; AGED; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; FUSION PROTEINS, BCR-ABL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HL-60 CELLS; HUMANS; KINETICS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REFERENCE STANDARDS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

ANTINEOPLASTIC AGENT; ASPARAGINASE; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ENOCITABINE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; KINETICS; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 85047699867     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402483     Document Type: Article

References (34)

1. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia
2. Expression of a distinctive BCR-ABL oncogene in Ph-positive acute lymphocytic leukemia (ALL)
3. Molecular heterogeneity of adult Philadelphia chromosome-positive acute lymphoblastic leukemia
4. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia
5. Cytogenetics and their prognostic value in childhood and adult acute lymphoblastic leukemia (ALL) excluding L3
6. Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance
7. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study 8762
8. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction
9. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
10. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia
11. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro
12. The molecular genetics of Philadelphia chromosomepositive leukemias
13. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
14. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction
15. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials CoALL-05-92
16. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults
17. Treatment of acute lymphoblastic leukemia
18. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation
19. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
20. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia
21. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia
22. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia
23. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)
24. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
25. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after bone marrow transplantation
26. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: Comparison of blood and bone marrow
27. Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction
28. Establishment and characterization of a new Ph1-positive ALL cell line (ALL/MIK) presenting bcr gene rearrangement on bcr-2 and ALL-type bcr/abl transcript: Suggestion of in vitro differentiation to monocytoid lineage
29. Human myeloid leukemia cell lines: A review
30. In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: Implications for autologous BMT
31. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage
32. Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients
33. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
34. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells